Bristol Myers Squibb Analysts Slash Their Forecasts Following Q3 Results
Portfolio Pulse from Lisa Levin
Bristol Myers Squibb & Co (NYSE:BMY) reported better-than-expected Q3 earnings with revenues of $10.966 billion and adjusted EPS of $2.00. However, the company's shares fell 3.8% to $50.94 following the announcement. Several analysts, including those from HSBC, Barclays, Morgan Stanley, William Blair, and BMO Capital, have revised their price targets and ratings for the company.
October 27, 2023 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol Myers Squibb's Q3 earnings beat expectations but its shares fell 3.8%. Several analysts have revised their price targets and ratings for the company, potentially impacting its stock price.
Bristol Myers Squibb reported better-than-expected Q3 earnings, but its shares fell following the announcement. This negative market reaction, combined with several analysts revising their price targets and ratings for the company, could potentially lead to a further decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100